Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gupta:2018:10.1016/S0140-6736(18)31776-8,
author = {Gupta, A and Mackay, J and Whitehouse, A and Godec, T and Collier, T and Pocock, S and Poulter, N and Sever, P},
doi = {10.1016/S0140-6736(18)31776-8},
journal = {Lancet},
pages = {1127--1137},
title = {Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial},
url = {http://dx.doi.org/10.1016/S0140-6736(18)31776-8},
volume = {392},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: In patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial. METHODS: ASCOT was a multicentre randomised trial with a 2×2 factorial design. UK-based patients with hypertension were followed up for all-cause and cardiovascular mortality for a median of 15·7 years (IQR 9·7-16·4 years). At baseline, all patients enrolled into the blood pressure-lowering arm (BPLA) of ASCOT were randomly assigned to receive either amlodipine-based or atenolol-based blood pressure-lowering treatment. Of these patients, those who had total cholesterol of 6·5 mmol/L or lower and no previous lipid-lowering treatment underwent further randomisation to receive either atorvastatin or placebo as part of the lipid-lowering arm (LLA) of ASCOT. The remaining patients formed the non-LLA group. A team of two physicians independently adjudicated all causes of death. FINDINGS: Of 8580 UK-based patients in ASCOT, 3282 (38·3%) died, including 1640 (38·4%) of 4275 assigned to atenolol-based treatment and 1642 (38·1%) of 4305 assigned to amlodipine-based treatment. 1768 of the 4605 patients in the LLA died, including 903 (39·5%) of 2288 assigned placebo and 865 (37·3%) of 2317 assigned atorvastatin. Of all deaths, 1210 (36·9%) were from cardiovascular-related causes. Among patients in the BPLA, there was no overall difference in all-cause mortality between treatments (adjusted hazard ratio [HR] 0·90, 95% CI 0·81-1·01, p=0·0776]), although significantly fewer deaths from stroke (adjusted HR 0·71, 0·53-0·97, p=0·0305) occurr
AU  - Gupta,A
AU  - Mackay,J
AU  - Whitehouse,A
AU  - Godec,T
AU  - Collier,T
AU  - Pocock,S
AU  - Poulter,N
AU  - Sever,P
DO  - 10.1016/S0140-6736(18)31776-8
EP  - 1137
PY  - 2018///
SN  - 0140-6736
SP  - 1127
TI  - Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
T2  - Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(18)31776-8
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30158072
UR  - https://www.sciencedirect.com/science/article/pii/S0140673618317768?via%3Dihub
UR  - http://hdl.handle.net/10044/1/63552
VL  - 392
ER  -
Download